tiprankstipranks
Advertisement
Advertisement

CMPX Stock Latest News

Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
RatingsCompass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
2d ago
CMPX
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
PremiumThe Fly
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
2d ago
CMPX
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
9d ago
MU
TU
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
PremiumThe Fly
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
9d ago
CMPX
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
PremiumThe Fly
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
9d ago
CMPX
Compass Therapeutics price target lowered to $6 from $12 at Stifel
PremiumThe FlyCompass Therapeutics price target lowered to $6 from $12 at Stifel
10d ago
CMPX
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
Premium
The Fly
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
10d ago
CMPX
Leerink says Compass data supports path forward for tovecimig in 2L BTC
Premium
The Fly
Leerink says Compass data supports path forward for tovecimig in 2L BTC
10d ago
CMPX
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
PremiumThe Fly
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
10d ago
VZ
WW
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
PremiumRatings
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
10d ago
CMPX
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
PremiumThe Fly
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
10d ago
CMPX
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
PremiumRatings
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
10d ago
CMPX
Morning Movers: Domino’s Pizza sinks following first quarter results
PremiumThe FlyMorning Movers: Domino’s Pizza sinks following first quarter results
10d ago
VZ
CPB
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
Premium
Company Announcements
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
10d ago
8K
CMPX
Compass Therapeutics reports additional COMPANION-002 study results
Premium
The Fly
Compass Therapeutics reports additional COMPANION-002 study results
10d ago
CMPX
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
PremiumRatings
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
1M ago
CMPX
Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
PremiumRatings
Buy Rating on Compass Therapeutics: Anticipating Pivotal Tovecimig Data as a Key Value Inflection Point in Advanced Biliary Tract Cancer
1M ago
CMPX
Compass Therapeutics reports Q4 EPS (9c), consensus (9c)
PremiumThe Fly
Compass Therapeutics reports Q4 EPS (9c), consensus (9c)
2M ago
CMPX
CMPX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CMPX Upcoming Earnings Report: What to Expect?
2M ago
CMPX
Buy Rating on Tovecimig Driven by Early Efficacy Signals and Differentiated Risk–Benefit Profile in Biliary Tract Carcinoma
PremiumRatingsBuy Rating on Tovecimig Driven by Early Efficacy Signals and Differentiated Risk–Benefit Profile in Biliary Tract Carcinoma
2M ago
CMPX
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know
Premium
Company Announcements
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know
3M ago
CMPX
3 Strong Buy Stocks With 100%+ Upside, According to Top Analysts, 2/16/2026
Premium
Market News
3 Strong Buy Stocks With 100%+ Upside, According to Top Analysts, 2/16/2026
3M ago
BTDR
CMPX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >